The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites
Authorized Users Only
2018
Authors
Ignjatović, Nenad
Penov Gaši, Katarina

Ajduković, Jovana

Kojić, Vesna V.

Marković, Smilja

Uskoković, Dragan

Article (Published version)

Metadata
Show full item recordAbstract
An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to target the lungs following intravenous administration. In this study, we used emulsification and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying contents of the derivative A, in order to examine the selective toxicity towards cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading process, and the content of the poorly water soluble derivative A was estimated directly via the DSC technique. The particles were spherical in shape with the d50 distribution varying between 167 and 231 nm, whereas the content of the derivative A ranged from 6.5 to 19.3 wt%. Cell-selective cytotoxicity was... examined simultaneously on two cell lines: human lung carcinoma (A549 ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 171). All particles exhibited nearly three times larger cytotoxicity towards cancer cells (A549) than towards healthy cells (MRC5), where the particles with the derivative A content of 6.5 wt% allowed for the viability of healthy cells >80%. Ninety-six hours after the treatment of cells with particles with different contents of derivative A (after incubation and recovery), recovery was faster in damaged healthy cells than in cancerous cells. © 2018 Elsevier B.V.
Keywords:
androstane / cell-selective cytotoxicity / hydroxyapatite / lung cancer / nanocarriersSource:
Materials Science and Engineering C, 2018, 89, 371-377Publisher:
- Elsevier
Funding / projects:
DOI: 10.1016/j.msec.2018.04.028
ISSN: 0928-4931
WoS: 000434239100039
Scopus: 2-s2.0-85045579234
Institution/Community
Институт техничких наука САНУ / Institute of Technical Sciences of SASATY - JOUR AU - Ignjatović, Nenad AU - Penov Gaši, Katarina AU - Ajduković, Jovana AU - Kojić, Vesna V. AU - Marković, Smilja AU - Uskoković, Dragan PY - 2018 UR - https://dais.sanu.ac.rs/123456789/3699 AB - An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to target the lungs following intravenous administration. In this study, we used emulsification and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying contents of the derivative A, in order to examine the selective toxicity towards cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading process, and the content of the poorly water soluble derivative A was estimated directly via the DSC technique. The particles were spherical in shape with the d50 distribution varying between 167 and 231 nm, whereas the content of the derivative A ranged from 6.5 to 19.3 wt%. Cell-selective cytotoxicity was examined simultaneously on two cell lines: human lung carcinoma (A549 ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 171). All particles exhibited nearly three times larger cytotoxicity towards cancer cells (A549) than towards healthy cells (MRC5), where the particles with the derivative A content of 6.5 wt% allowed for the viability of healthy cells >80%. Ninety-six hours after the treatment of cells with particles with different contents of derivative A (after incubation and recovery), recovery was faster in damaged healthy cells than in cancerous cells. © 2018 Elsevier B.V. PB - Elsevier T2 - Materials Science and Engineering C T1 - The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites SP - 371 EP - 377 VL - 89 DO - 10.1016/j.msec.2018.04.028 UR - https://hdl.handle.net/21.15107/rcub_dais_3699 ER -
@article{ author = "Ignjatović, Nenad and Penov Gaši, Katarina and Ajduković, Jovana and Kojić, Vesna V. and Marković, Smilja and Uskoković, Dragan", year = "2018", abstract = "An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to target the lungs following intravenous administration. In this study, we used emulsification and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying contents of the derivative A, in order to examine the selective toxicity towards cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading process, and the content of the poorly water soluble derivative A was estimated directly via the DSC technique. The particles were spherical in shape with the d50 distribution varying between 167 and 231 nm, whereas the content of the derivative A ranged from 6.5 to 19.3 wt%. Cell-selective cytotoxicity was examined simultaneously on two cell lines: human lung carcinoma (A549 ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 171). All particles exhibited nearly three times larger cytotoxicity towards cancer cells (A549) than towards healthy cells (MRC5), where the particles with the derivative A content of 6.5 wt% allowed for the viability of healthy cells >80%. Ninety-six hours after the treatment of cells with particles with different contents of derivative A (after incubation and recovery), recovery was faster in damaged healthy cells than in cancerous cells. © 2018 Elsevier B.V.", publisher = "Elsevier", journal = "Materials Science and Engineering C", title = "The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites", pages = "371-377", volume = "89", doi = "10.1016/j.msec.2018.04.028", url = "https://hdl.handle.net/21.15107/rcub_dais_3699" }
Ignjatović, N., Penov Gaši, K., Ajduković, J., Kojić, V. V., Marković, S.,& Uskoković, D.. (2018). The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites. in Materials Science and Engineering C Elsevier., 89, 371-377. https://doi.org/10.1016/j.msec.2018.04.028 https://hdl.handle.net/21.15107/rcub_dais_3699
Ignjatović N, Penov Gaši K, Ajduković J, Kojić VV, Marković S, Uskoković D. The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites. in Materials Science and Engineering C. 2018;89:371-377. doi:10.1016/j.msec.2018.04.028 https://hdl.handle.net/21.15107/rcub_dais_3699 .
Ignjatović, Nenad, Penov Gaši, Katarina, Ajduković, Jovana, Kojić, Vesna V., Marković, Smilja, Uskoković, Dragan, "The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites" in Materials Science and Engineering C, 89 (2018):371-377, https://doi.org/10.1016/j.msec.2018.04.028 ., https://hdl.handle.net/21.15107/rcub_dais_3699 .